The increase of $32.2 million was primarily due to (i) $22.3 million of higher direct costs attributable to increased spending with our other programs, (ii) $10.1 million of higher direct costs associated with our MRGPRX2 program, including an increase of $6.9 million in external clinical development expenses, (iii) $9.9 million of higher employee-related costs as a result of increased headcount as we grow our business, (iv) $2.0 million of higher facility-related and office costs as we expanded our office space to accommodate 108 higher occupancy and larger operational activities and (v) $1.2 million of increased direct costs associated with our PTH1R program
Certain groups face higher risk of severe outcomes from norovirus
Meaning it helps fight leaky gut, helps with bloating and supports the digestive system
Study: Income, BMI linked to CCE completion by Doug Brunk Danish screening data identify clinical and socioeconomic factors that significantly influence the likelihood of a complete colon capsule examination
Actual product packaging, labeling, and appearance may differ
Your provider will determine whether switching makes clinical sense and, if approved, establish a transition timeline that minimizes metabolic disruption
